Hypertension in Diabetic Nephropathy: Epidemiology, Mechanisms, and Management

Advances in Chronic Kidney Disease

Volumn 18, Issue 1, 2011, Pages 28-41

  Van Buren, Peter N ^a   Toto, Robert ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Albuminuria; Angiotensin II; CKD; Diabetic nephropathy; Hypertension

Indexed keywords

ALISKIREN; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; AVOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENDOTHELIN 1; HYDRALAZINE; IRBESARTAN; LISINOPRIL; LOSARTAN; MINOXIDIL; NITRIC OXIDE; OLMESARTAN; PLACEBO; RAMIPRIL; SODIUM; SPIRONOLACTONE; TELMISARTAN; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL; VERAPAMIL;

ALBUMINURIA; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL (TOPIC); CONGESTIVE HEART FAILURE; DIABETIC NEPHROPATHY; DISEASE ACTIVITY; DISEASE COURSE; DRUG EFFICACY; DRUG INHIBITION; DRUG SAFETY; ENDOTHELIAL DYSFUNCTION; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERTENSION; HYPOKALEMIA; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY TUBULE ABSORPTION; LUNG EDEMA; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETROSPECTIVE STUDY; REVIEW; SODIUM BALANCE; UNITED STATES;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; DIABETIC NEPHROPATHIES; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; RECEPTORS, MINERALOCORTICOID; RENIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 78651112164     PISSN: 15485595     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ackd.2010.10.003     Document Type: Review

References (100)

1. Horl M., Horl W. Hemodialysis associated hypertension: pathophysiology and therapy. Am J Kidney Dis 2002, 39:227-244.
2. Excerpts from the United States renal data system-2009 Annual Data Report: atlas of chronic kidney disease and end stage renal disease in the United States. Incidence and prevalence. Am J Kidney Dis 2010, 55(Suppl 1):S231-S240.
3. Excerpts from the United States Renal Data System-2009 Annual Data Report: atlas of chronic kidney disease and end stage renal disease in the United States. Chronic kidney disease in the NHANES population. Am J Kidney Dis 2010, 55(Suppl 1):S35-S48.
4. Schwartz, Melvin M., Leonard-Martin T., et al. Renal pathology patterns in type II diabetes mellitus: relationship with retinopathy. Nephrol Dial Transplant 1998, 13:2547-2552.
5. National Kidney Foundation KDOQI™ Clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007, 49(Suppl 2):S1-S180.
6. Parving H.H., Gall M.A., Skøtt P., et al. Prevalence and causes of albuminuria in non insulin-dependent diabetic patients. Kidney Int 1992, 4:758-762.
7. Epstein M., Sowers J. Diabetes mellitus and hypertension. Hypertension 1992, 19:403-418.
8. Norgaard K., Feldt-Rasmussen B., Johnsen K., et al. Prevalence of hypertension in type 1 (insulin dependent) diabetes mellitus. Diabetologia 1990, 33:407-410.
9. Parving H., Hommel E., Mathiesen E., et al. Prevalence of microalbuminuria, arterial hypertension, retinopathy, and neuropathy in patients with insulin dependent diabetes. Br Med J 1988, 296:156-160.
10. Lurbe E., Redon J., Kesani A. Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N Engl J Med 2002, 347:797-805.
11. Fagerudd J.A., Tarnow L., Jacobsen P., et al. Predisposition to essential hypertension and development of diabetic nephropathy in IDDM patients. Diabetes 1998, 47:439-444.
12. Ismail N., Becker B., Strzelczyk P., et al. Renal disease and hypertension in non-insulin dependent diabetes mellitus. Kidney Int 1999, 55:1-28.
13. Keller C., Bergis K., Filser D., et al. Renal findings in patients with short-term type 2 diabetes. J Am Soc Nephrol 1996, 7:2627-2635.
14. Bakris G., Williams M., Dworkin L., et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis 2000, 36:646-661.
15. Freedman B., Bostrom M., Daeihagh P., Boweden D. Genetic factors in diabetic nephropathy. Clin J Am Soc Nephrol 2007, 2:1306-1316.
16. Iynegar S., Freedman B., Sedor J. Mining the genome for susceptibility to diabetic nephropathy: the role of large-scale studies and consortia. Semin Nephrol 2007, 27:208-222.
17. Rajagopalan S., Kurz S., Munzel T., et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. J Clin Invest 1996, 97:1916-1923.
18. Price D., Porter L., Gordon M., et al. The paradox of the low renin state in diabetic nephropathy. J Am Soc Nephrol 1999, 10:2382.
19. Price D., De'Oliveira J., Fisher N., et al. The state and responsiveness of the renin-angiotensin-aldosterone system in patients with type 2 diabetes mellitus. Am J Hypertens 1999, 12:348.
20. Anderson F., Jung F., Ingelfinger J.R. Renal rennin-angiotensin system in diabetes: functional, immunohistochemical, and molecular biological correlations. Am J Renal Phys 1993, 265(4 Pt. 2):F477-F486.
21. Mizuiri S., Yoshikawa H., Tanegashima M., et al. Renal ACE immunohistochemical localization in NIDDM patients with nephropathy. Am J Kidney Dis 1998, 31:301-307.
22. Konoshita T., Wakahara S., Mizuno, et al. Tissue gene expression of rennin-angiotensin system in human type 2 diabetic nephropathy. Diabetes Care 2006, 29:848-852.
23. Danilcyzk U., Penninger J. Angiotensin-converting enzyme II in the heart and kidney. Circ Res 2006, 98:463-471.
24. Tikellis C., Johnston, Forbes J., et al. Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy. Hypertension 2003, 41:392-397.
25. De Chatel R., Weidmann P., Flammer J., et al. Sodium, rennin, aldosterone, catecholamines, and blood pressure in diabetes mellitus. Kidney Int 1977, 12:412-421.
26. Brands M., Labazi H. Role of glomerular filtration rate in controlling blood pressure early in diabetes. Hypertension 2008, 52:188-194.
27. Tuck M., Corry D., Trujillo A. Salt sensitive blood pressure and exaggerated vascular reactivity in the hypertension of diabetes mellitus. Am J Med 1990, 88:210-216.
28. Imanishi M., Yoshioka K., Okumura M., et al. sodium sensitivity related to albuminuria appearing before hypertension in type 2 diabetic patients. Diabetes Care 2001, 24:111-116.
29. DeFronzo R. The effect of insulin on renal sodium metabolism. Diabetologia 1981, 21:165-171.
30. Koomans H., Roos J., Dourhout Mees E., et al. Soidum balance in renal failure: a comparison of patients with normal subjects under extremes of sodium intake. Hypertension 1985, 7:714-721.
31. Gu J.W., Anand V., Shek E., et al. Sodium induces hypertrophy of cultured myocardial myoblasts and vascular smooth muscle cells. Hypertension 1998, 31:1083-1087.
32. Spallone V., Gambardella S., Maiello M., et al. Relationship between autonomic neuropathy, 24-h blood pressure profile, and nephropathy in normotensive IDDM patients. Diabetes Care 1994, 17:578-584.
33. Liniger C., Favre L., Assal J. Twenty-four hour blood pressure and heart rate profiles of diabetic patients with abnormal cardiovascular reflexes. Diabetic Med 1991, 8:420-427.
34. Nielsen F., Hansen H., Jacobsen P. Increased sympathetic activity during sleep and nocturnal hypertension in Type 2 diabetic patients with diabetic nephropathy. Diabetic Med 1999, 16:555-562.
35. Facchini F., Stoohs R., Reaven G. Enhanced sympathetic nervous system activity: the linchpin between insulin resistance, hyperinsulinemia, and heart rate. Am J Hypertens 1996, 9:1013-1017.
36. Achan V., Broadhead M., Malaki M., et al. Asymetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethyl dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 2003, 23:1455-1459.
37. Abbasi F., Asagmi T., Cooke J., et al. Plasma concentrations of asymetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol 2001, 88:1201-1203.
38. Kielstein J., Boger R., Bode-Boger S. Asymetric dimethylarginine concentrations differ in patients with end stage renal disease: relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol 1999, 10:594-600.
39. Zoccali C., Bode-Boger S., Mallamaci F., et al. Plasma concentrations of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001, 358:2113-2117.
40. Tarnow L., Hovind P., Teerlink T., et al. Elevated plasma asymetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes. Diabetes Care 2004, 27:765-769.
41. Matsuguma K., Ueda S., Yamagashi S., et al. Molecular mechanism for elevation of asymetric dimethylarginine and its role for hypertension in chronic kidney disease. J Am Soc Nephrol 2006, 17:2176-2183.
42. Muniyappa R., Quon M. Insulin action and insulin resistance in vascular endothelium. Curr Opin Nutr Metab Care 2007, 10:523.
43. Donatelli M., Colletti I., Bucalo M., et al. Plasma endothelin levels in NIDDM patients with macroangiopathy. Diabetes Res 1994, 25:159-164.
44. Koyama H., Tabata T., Nishzawa T., et al. Plasma endothelin levels in patients with uremia. Lancet 1989, 1:991-992.
45. Dhaun N., Ferro C., Davenport A., et al. Hemodynamic and renal effects of endothelin receptor antagonism in patients with chronic kidney disease. Nephrol Dial Transplant 2007, 22:3228.
46. Prabhakar Sharma Role of nitric oxide in diabetic nephropathy. Semin Nephrol 2004, 24:333-334.
47. Fitzgerald S.M., Brands M.W. Nitric Oxide may be required to prevent hypertension at the onset of diabetes. Am J Physiol 2000, 279:E762-E768.
48. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414:813-820.
49. Spittle M., Hoenrich N., Handelman G., et al. Oxidative stress and inflammation in hemodialysis patients. Am J Kidney Dis 2001, 38:1408-1413.
50. Ceballos-Picot I., Witko-Sarsat V., Merad-Boudia M., et al. Glutathione antioxidant system as a marker of oxidative stress in chronic renal failure. Free Radic Biol Med 1996, 21:845-853.
51. Vaziri N., Oveisi F., Ding Y. Role of increased oxygen free radical activity in the pathogenesis of uremic hypertension. Kidney Int 1998, 53:1748.
52. Prabhakar S., Starnes J., Shi S., et al. Diabetic nephropathy is associated with oxidative stress and decreased renal nitric oxide production. J Am Soc Nephrol 2007, 18:2945-2952.
53. Griendling K., Ollerenshaw J., Minieri C., et al. Angiotensin II stimulates NADH and NADPH activity in cultured vascular smooth muscle cells. Circ Res 1994, 74:1141-1148.
54. Ogawa S., Mori T., Nako, et al. Angiotensin II type 1 receptor blockers reduce urinary oxidative stress markers in hypertensive diabetic nephropathy. Hypertension 2006, 47:699-705.
55. Li L., Fink G., Watts S., et al. Endothelin 1 increases vascular superoxide via endothelin a-NADPH oxidase pathway in low renin hypertension. Circulation 2003, 107:1053-1058.
56. Palmer B. Impaired autoregulation: implications for the genesis of hypertension and hypertension induced renal injury. Am J Med Sci 2001, 321:388-400.
57. Gnudi L., Viberti G., Raij L., et al. GLUT-1 overexpression: link between hemodynamic and metabolic factors in glomerular injury. Hypertension 2003, 42:19-24.
58. American Diabetes Association Diabetic nephropathy. Diabetes Care 2002, 25:S82-S89.
59. Mogensen C.E. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. Br Med J 1982, 285:685-688.
60. Parving H.H., Andersen A.R., Smidt U.M., et al. Effect of antihypertensive treatment on kidney function in diabetic nephropathy. Br Med J 1987, 294:1443-1447.
61. Parving H.H., Smidt U.M., Andersen A.R., et al. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1983, 321:1175-1179.
62. Lewis E.J., Hunsicker L.G., Bain R.P., et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993, 329:1456-1462. The Collaborative Study Group.
63. Parving H.H., Hommel E., Jensen B.R., et al. Long-term beneficial effect of ACE inhibition on diabetic nephropathy in normotensive type 1 diabetic patients. Kidney Int 2001, 60:228-234.
64. Lewis E.J., Hunsicker L.G., Clarke W.R., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851-860.
65. Brenner B.M., Cooper M.E., de Zeeuw D., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869.
66. Parving H.H., Lehnert H., Brochner-Mortensen J., et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001, 345:870-878.
67. Ruggenenti P., Fassi A., Ilieva A., et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004, 351:1941-1951.
68. Haller H., Ito S., Janusszewicz A., et al. Prevention of microalbuminuria in type 2 diabetes (roadmap trial). J Hypertens 2010, 28:e323.
69. Mauer M., Zinman B., Gardiner R., et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 2009, 361:40-51.
70. Barnett A., Bain S., Bouter P., et al. Angiotensin receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004, 351:1952-1962.
71. Rossing K., Jacobsen P., Pietraszek L., et al. Renoprotective effects of adding angiotensin II receptor blocker to a maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double blind crossover trial. Diabetes Care 2003, 26:2268-2274.
72. Jacobsen P., Andersen S., Jensen B., et al. Additive effect of ace inhibition and angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. J Am Soc Nephrol 2003, 14:992-999.
73. Jacobsen P., Andersen S., Rossing K., et al. Dual blockade of the rennin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney Int 2003, 63:1874-1880.
74. Andersen N.H., Poulsen P.L., Knudsen S.T., et al. Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: the CALM II study. Diabetes Care 2005, 28:273-277.
75. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008, 358:1547-1559. ON TARGET investigators.
76. Department of Veterans Affairs; Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy VA NEPHRON-D Study: Nephropathy iN Diabetes Study. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2010 Oct 26]. Available from: NLM Identifier NCT00555217. http://www.clinicaltrials.gov/ct2/show/NCT00555217.
77. Mann J., Schmieder R., McQueen, et al. Renal outcomes with telmisartan, ramipril, or both in people at high vascular risk (the ONTARGET study): a multicentre, randomized, double-blind, controlled trial. Lancet 2008, 372:547-553.
78. Urata H., Strobel F., Ganten D. Widespread distribution of human chymase. J Hypertens 1994, 12:S17-S22.
79. Persson F., Rossing P., Schjoedt K., et al. Time course of the antiproteinuric and antihypertensive effects of the direct rennin inhibition in type 2 diabetes. Kidney Int 2008, 73:1419-1425.
80. Parving H.H., Persson F., Lewis J., et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008, 358:2433-2446.
81. Persson F., Rossing P., Reinhard H. Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension and albuminuria. Diabetes Care 2009, 32:1873-1879.
82. Novartis; Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (ALTITUDE). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2010 Oct 26]. Available from ; NLM identifier 00549757. http://www.clinicaltrials.gov/ct2/show/NCT00549757.
83. Sato A., Hayashi K., Naruse M., et al. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003, 41:64-68.
84. Schjoedt K.J., Andersen S., Rossing P., et al. Aldosterone escape during blockade of the rennin angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia 2004, 47:1936-1939.
85. Bomback A.S., Klemmer P.J. The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol 2007, 3:486-492.
86. Schjoedt K., Rossing K., Juhl T., et al. Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int 2005, 68:2829-2836.
87. Schjoedt K., Rossing K., Juhl T., et al. Beneficial impact of spironolactone on nephritic range albuminuria in diabetic nephropathy. Kidney Int 2006, 70:S36-S42.
88. Mehdi U., Adams-Huet B., Raskin P., et al. Addition of angiotensin receptor blocker or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol 2009, 20:2641-2650.
89. Khosla N., Kalaitzidis R., Bakris G. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am J Nephrol 2009, 30:418-424.
90. Mann J., Green D., Jamerson K., et al. Avosentan for overt diabetic nephropathy. J Am Soc Nephrol 2010, 21:527-535.
91. Saydah S.H., Fradkin J., Cowie C.C. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004, 291:335-342.
92. Joss F., Ferguson C., Brown C., et al. Intensified treatment of patients with type 2 diabetes mellitus and overt nephropathy. QJM 2004, 97:219-227.
93. Berl T., Hunsicker L., Lewis J., et al. Impact of achieved blood pressure on cardiovascular outcomes in the irbesartan diabetic nephropathy trial. J Am Soc Nephrol 2005, 16:2170-2179.
94. Effects of intensive blood pressure control in type 2 diabetes mellitus. N Engl J Med 2010, 362:1575-1585. The ACCORD Study Group.
95. Bakris G., Weir M., Shanifar S., et al. Effects of blood pressure level on progression of diabetic nephropathy. Arch Int Med 2003, 163:1555-1565.
96. De Galan B., Perkovic V., Ninomiya T. Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol 2009, 20:883-892.
97. Bakris G., Sarafidis P., Weir M., et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomized controlled trial. Lancet 2010, 375:1173-1181.
98. Zillich A., Garg J., Basu S., et al. Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension 2006, 48:219-224.
99. Van Buren PN, Huet-Adams B, Toto R. Effective antihypertensive therapies in high risk patients with diabetic nephropathy. J Investig Med. In press.
100. Kunz R., Friedrich C., Wolbers M., et al. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin-angiotensin system on proteinuria in renal disease. Ann Int Med 2008, 148:30-48.